Gastroenterology

Top Story

TOUCHSTONE: 2-year data support phase 3 trial of ozanimod in UC

TOUCHSTONE: 2-year data support phase 3 trial of ozanimod in UC
October 16, 2017

ORLANDO — Long-term treatment with ozanimod remained safe and well-tolerated with good compliance and durable efficacy at 2 years follow-up among patients with moderate-to-severe ulcerative colitis, according to findings from the TOUCHSTONE extension trial presented here.

“We believe these data provide evidence of the durable efficacy of long-term treatment with ozanimod and we have initiated a phase 3 trial, but it will be a bit until it is complete and data become available,” William J. Sandborn, MD, of the University of California, La Jolla, Calif., said during his presentation.

Meeting News

ACG elects Irving M. Pike 2017-18 president

October 16, 2017
ORLANDO – American College of Gastroenterology 2017-2018 president Irving M. Pike, MD, FACG, officially assumed his position during the World Congress of…
FDA News

FDA clears minimally invasive, robotically-assisted surgical device

October 16, 2017
TransEnterix Surgical received FDA clearance for its Senhance System, a new robotically-assisted surgical device, or RASD, designed to facilitate minimally invasive…
Meeting NewsVideo

WCOG at ACG 2017 highlights include early-onset colon cancer, smoking and GI disease, burnout

October 16, 2017
ORLANDO — In this exclusive video from the World Congress of Gastroenterology at ACG 2017, ACG Public Relations Committee Chair Jordan J. Karlitz, MD, FACG, of…
In the Journals

Women on biologics are likely to halt these drugs once pregnant

October 16, 2017
Among pregnant women taking biologics for autoimmune diseases, there is a significant likelihood of discontinuation in certain populations, according to findings…
More Headlines »
Advertisement
Advertisement